Amarin to Present at the Leerink Swann Global Healthcare Conference 2013

Amarin to Present at the Leerink Swann Global Healthcare Conference 2013

BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced that John F. Thero, Amarin's President, is scheduled to
present a general company update at the Leerink Swann Global Healthcare
Conference 2013 on Wednesday, February 13, 2013, at 4:00 p.m. ET. This
conference will be held at the Waldorf Astoria in New York City.

A live audio webcast of the presentation will be available at:

http://leerink.metameetings.com/webcasts/healthcare13/directlink?p=17

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl),
Amarin's first FDA approved product, is a patented, ultra pure omega-3 fatty
acid product comprising not less than 96% EPA. For more information about
Vascepa visit www.vascepa.com. For more information about Amarin visit
www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

CONTACT: Stephen D. Schultz
         Senior Director, Investor Relations and
         Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo